Subtopic Deep Dive

Endothelial Progenitor Cells in Angiogenesis
Research Guide

What is Endothelial Progenitor Cells in Angiogenesis?

Endothelial progenitor cells (EPCs) are bone marrow-derived cells recruited to tumors that contribute to angiogenesis through direct incorporation into vessels and paracrine signaling.

EPCs support tumor neovascularization by homing to hypoxic sites and promoting vessel formation (Yamaguchi et al., 2003). Their role involves SDF-1 mediated recruitment for ischemic neovascularization, with over 1100 citations. Studies link EPCs to VEGF-driven angiogenesis in cancer models (Ferrara, 2004; Hicklin and Ellis, 2004).

Curated Papers

Key Challenges

Why It Matters

Targeting EPC recruitment enhances anti-angiogenic therapies by blocking bone marrow contributions to tumor vessels, as shown in models using VEGF receptor inhibitors (Klement et al., 2000). EPCs provide paracrine support to existing endothelium, offering combinatorial strategies with pericytes targeting (Bergers et al., 2003). Hypoxia-induced EPC mobilization sustains tumor vascularization resistant to VEGF blockade alone (Muz et al., 2015). This approach improves outcomes in pancreatic islet cancer models (Hanahan and Folkman, 1996).

Key Research Challenges

EPC Recruitment Mechanisms

Tumors recruit EPCs via SDF-1 chemokines from bone marrow, but signaling pathways vary by tumor type (Yamaguchi et al., 2003). Hypoxia drives mobilization yet leads to dysfunctional vessels (Muz et al., 2015). Distinguishing EPC contributions from resident endothelium remains difficult (Aird, 2007).

Paracrine vs Structural Roles

EPCs exert paracrine effects via VEGF and PlGF without full vessel incorporation, complicating targeting (Carmeliet et al., 2001). Their limited direct engraftment questions structural importance (Lugano et al., 2019). Quantifying paracrine impacts requires advanced imaging (Hanahan and Folkman, 1996).

Therapeutic Targeting Specificity

Inhibitors like SU5416 block EPC-supported angiogenesis but spare mature vessels (Bergers et al., 2003). Resistance emerges from hypoxia-adapted EPCs (Muz et al., 2015). Combinatorial low-dose therapies with vinblastine show sustained regression (Klement et al., 2000).

Essential Papers

Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis

Douglas Hanahan, Judah Folkman · 1996 · Cell · 6.9K citations

Vascular Endothelial Growth Factor: Basic Science and Clinical Progress

Napoleone Ferrara · 2004 · Endocrine Reviews · 3.6K citations

Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and an angiogenic inducer in a variety of in vivo models. Hypoxia has been shown to be a major inducer of ...

Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis

Daniel J. Hicklin, Lee M. Ellis · 2004 · Journal of Clinical Oncology · 3.0K citations

New blood vessel formation (angiogenesis) is a fundamental event in the process of tumor growth and metastatic dissemination. Hence, the molecular basis of tumor angiogenesis has been of keen inter...

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy

Barbara Muz, Pilar de la Puente, Feda Azab et al. · 2015 · Hypoxia · 2.0K citations

Hypoxia is a non-physiological level of oxygen tension, a phenomenon common in a majority of malignant tumors. Tumor-hypoxia leads to advanced but dysfunctional vascularization and acquisition of e...

Tumor angiogenesis: causes, consequences, challenges and opportunities

Roberta Lugano, Mohanraj Ramachandran, Anna Dimberg · 2019 · Cellular and Molecular Life Sciences · 1.8K citations

Abstract Tumor vascularization occurs through several distinct biological processes, which not only vary between tumor type and anatomic location, but also occur simultaneously within the same canc...

Phenotypic Heterogeneity of the Endothelium

William C. Aird · 2007 · Circulation Research · 1.7K citations

Endothelial cells, which form the inner cellular lining of blood vessels and lymphatics, display remarkable heterogeneity in structure and function. This is the first of a 2-part review focused on ...

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions

Peter Carmeliet, Lieve Moons, Aernout Luttun et al. · 2001 · Nature Medicine · 1.7K citations

Reading Guide

Foundational Papers

Start with Hanahan and Folkman (1996) for angiogenic switch context (6862 citations), then Ferrara (2004) on VEGF basics (3650 citations), and Yamaguchi et al. (2003) for EPC recruitment mechanisms (1145 citations).

Recent Advances

Study Lugano et al. (2019) on tumor vascular heterogeneity (1813 citations) and Muz et al. (2015) on hypoxia-EPC links (2003 citations).

Core Methods

SDF-1 chemokine assays for recruitment (Yamaguchi et al., 2003); VEGFR inhibitors like SU5416 for targeting (Bergers et al., 2003); hypoxia models for mobilization (Muz et al., 2015).

How PapersFlow Helps You Research Endothelial Progenitor Cells in Angiogenesis

Discover & Search

Research Agent uses citationGraph on Yamaguchi et al. (2003) to map EPC recruitment links to SDF-1 and VEGF papers like Ferrara (2004), revealing 1145+ citation clusters. exaSearch queries 'EPC SDF-1 tumor angiogenesis' uncovers hidden reviews; findSimilarPapers expands to hypoxia-EPC works (Muz et al., 2015).

Analyze & Verify

Analysis Agent runs readPaperContent on Yamaguchi et al. (2003) to extract SDF-1 ex vivo data, then verifyResponse with CoVe cross-checks claims against Hicklin and Ellis (2004). runPythonAnalysis processes vessel density stats from Bergers et al. (2003) via pandas for GRADE B-verified correlations in Python sandbox.

Synthesize & Write

Synthesis Agent detects gaps in EPC-pericyte interactions post-Bergers et al. (2003), flags VEGF-PlGF contradictions (Carmeliet et al., 2001). Writing Agent applies latexEditText to draft reviews, latexSyncCitations for 10+ papers, and latexCompile for publication-ready figures; exportMermaid diagrams EPC homing pathways.

Use Cases

"Analyze SDF-1 EPC recruitment data from Yamaguchi 2003 with statistics"

Research Agent → searchPapers 'Yamaguchi SDF-1 EPC' → Analysis Agent → readPaperContent + runPythonAnalysis (pandas quantify homing efficiency) → CSV export of vessel formation metrics.

"Write LaTeX review on EPC roles in tumor angiogenesis citing Hanahan Folkman"

Synthesis Agent → gap detection in EPC gaps → Writing Agent → latexEditText (intro) → latexSyncCitations (15 papers) → latexCompile → PDF with EPC-VEGF diagram.

"Find code for EPC tracking in angiogenesis models"

Research Agent → paperExtractUrls (Yamaguchi 2003) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on vessel segmentation scripts.

Automated Workflows

Deep Research workflow scans 50+ EPC papers via searchPapers on 'endothelial progenitor cells tumor angiogenesis', chains citationGraph to Yamaguchi et al. (2003), outputs structured report with GRADE scores. DeepScan applies 7-step CoVe to verify Muz et al. (2015) hypoxia-EPC claims against Ferrara (2004). Theorizer generates hypotheses on EPC-PlGF synergies from Carmeliet et al. (2001).

Try Doxa for Endothelial Progenitor Cells in Angiogenesis Research

Frequently Asked Questions

What defines endothelial progenitor cells in angiogenesis?

EPCs are bone marrow-derived cells that home to ischemic sites via SDF-1, incorporating into vessels or providing paracrine VEGF support (Yamaguchi et al., 2003).

What methods track EPCs in tumors?

Ex vivo expansion and SDF-1 assays measure recruitment; imaging distinguishes EPC engraftment from endothelium (Yamaguchi et al., 2003; Aird, 2007).

What are key papers on EPCs in cancer angiogenesis?

Yamaguchi et al. (2003, 1145 citations) on SDF-1 recruitment; Bergers et al. (2003, 1223 citations) on EPC-pericyte targeting; Hanahan and Folkman (1996, 6862 citations) on angiogenic switch.

What open problems exist in EPC research?

Quantifying paracrine vs. structural roles; overcoming hypoxia-induced resistance; tumor-specific EPC heterogeneity (Muz et al., 2015; Lugano et al., 2019).